Amylyx Pharma Q3 EPS $0.30 Misses $0.44 Estimate, Sales $102.69M Miss $114.26M Estimate
Portfolio Pulse from bharat@benzinga.com
Amylyx Pharma (NASDAQ:AMLX) reported Q3 earnings of $0.30 per share, missing the analyst consensus estimate of $0.44 by 31.82%. The company also reported quarterly sales of $102.69 million, missing the analyst consensus estimate of $114.26 million by 10.12%. However, this represents a significant increase from the same period last year.
November 09, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amylyx Pharma's Q3 earnings and sales missed analyst estimates, which could negatively impact the stock in the short term. However, the YoY growth could be seen as a positive sign.
Amylyx Pharma's Q3 earnings and sales missed analyst estimates, which could lead to a decrease in the stock price as investors may see this as a sign of underperformance. However, the significant YoY growth could be seen as a positive sign, potentially mitigating some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100